All products are for laboratory research use only. Not for human consumption.
Metabolic · Visceral Reducer
The Metabolic Targeter
RM 380
Sculpt your sovereign silhouette. Tesamorelin 10 mg specifically targets deep, stubborn metabolic reserves, refining your core for a naturally firm, elegant waistline.
For research use only. Not for human or veterinary consumption. This product is not a medicine and is not intended to diagnose, treat, cure or prevent any disease.
Overview
Tesamorelin (TH9507) is the only growth hormone-releasing hormone analogue to achieve FDA approval (as Egrifta). Its Phase 3 clinical program produced the most comprehensive human GH secretagogue dataset available: -18% visceral adipose tissue, improved lipid profiles, reduced liver fat, and a validated long-term safety database — all impossible to achieve with research-only compounds.
Mechanism of action
Direct pituitary GHRH receptor activation — identical to endogenous GHRH
-18% visceral adipose tissue in Phase 3 randomized controlled trial
Direct hepatic lipid reduction independent of systemic fat loss
Key finding Tesamorelin achieved -18% visceral adipose tissue in Phase 3 FDA trial — the single largest visceral fat reduction ever demonstrated in a government-approved Phase 3 clinical trial. No other GH secretagogue has a Phase 3 dataset; Tesamorelin is the uniquely validated choice for visceral fat and metabolic research.
Key research findings
Visceral adipose tissue reduction at 26 weeks in Phase 3 RCT — primary endpoint achieved
Falutz J et al. N Engl J Med, 2007Tesamorelin (Egrifta) received FDA approval in 2010 — the only GHRH analogue ever approved
FDA approval NDA 022505, 2010Significant improvement in triglycerides and LDL-cholesterol profiles in Phase 3 subjects
Falutz J et al. AIDS, 2010Reduction in hepatic fat content and improvement in liver enzymes — anti-NAFLD evidence
Falutz J et al. AIDS, 2011Research areas
The most validated GH secretagogue for metabolic research — FDA Phase 3 visceral fat data no other compound possesses.
Triglyceride and LDL improvement alongside visceral fat reduction — comprehensive cardiovascular risk profile.
Anti-steatotic mechanism independent of weight loss — unique hepatic lipid reduction data.
The most physiologically faithful GHRH stimulus — structurally identical to endogenous GHRH(1-44).
Safety profile
Tesamorelin has the most comprehensive human safety database of any GH secretagogue — Phase 3 data from 400+ subjects over 52 weeks. This makes it the most evidence-based choice for research requiring validated human safety data.
GH stimulation elevates IGF-1 — oncology model consideration
GH reduces insulin sensitivity — monitor in diabetic models
Peripheral edema documented in 12% Phase 3 — dose-dependent
Joint discomfort reported in 7% Phase 3 — common GH class effect
Molecular profile
Frequently asked questions
Tesamorelin (Egrifta) received FDA approval in 2010 for HIV-associated lipodystrophy — the accumulation of visceral abdominal fat caused by antiretroviral therapy. The Phase 3 trials were conducted specifically in this population. The FDA reviewed and approved the complete Phase 3 dataset showing -18% visceral fat reduction, lipid improvement, and long-term safety.
FDA approval of Tesamorelin means it has completed the most rigorous clinical evaluation of any GHRH analogue — including Phase 3 RCTs, long-term safety follow-up, and regulatory scrutiny. This produces a human safety and efficacy dataset that no research-only compound possesses. For visceral fat, metabolic, and hepatic research, Tesamorelin provides validation depth that CJC-1295 or Ipamorelin (Phase 1/2 only) cannot match.
Both are GHRH analogues but engineered differently. CJC-1295 uses DAC technology (albumin binding) for a 6-8 day half-life. Tesamorelin uses a trans-3-hexenoic acid N-terminal modification that improves stability without albumin binding — producing a shorter half-life but rapid onset and the specific pharmacokinetic profile evaluated in Phase 3. Tesamorelin has FDA validation; CJC-1295 does not.
Tesamorelin stimulates GH secretion from the pituitary. GH activates hormone-sensitive lipase in adipose tissue — increasing lipolysis (fat breakdown). GH specifically affects visceral adipose tissue (VAT) more than subcutaneous fat, because VAT adipocytes express more GH receptors. The -18% VAT reduction reflects this selective mobilization of the metabolically dangerous visceral fat depot.
Yes. Phase 3 data showed hepatic fat reduction and liver enzyme improvement beyond what would be expected from weight loss alone. GH directly activates hepatic lipid metabolism through liver-specific GH receptor signaling — an anti-steatotic mechanism independent of the systemic fat loss effect. This makes Tesamorelin particularly relevant for NAFLD/NASH research.
References
